Westwood Management Corp IL maintained its stake in shares of Johnson & Johnson (NYSE:JNJ) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,850 shares of the company’s stock at the close of the second quarter. Westwood Management Corp IL’s holdings in Johnson & Johnson were worth $642,000 as of its most recent SEC filing.
Other large investors also recently made changes to their positions in the company. Lau Associates LLC increased its holdings in shares of Johnson & Johnson by 12.8% during the first quarter. Lau Associates LLC now owns 46,878 shares of the company’s stock worth $5,839,000 after buying an additional 5,335 shares in the last quarter. Lynch & Associates IN increased its holdings in shares of Johnson & Johnson by 0.9% during the second quarter. Lynch & Associates IN now owns 93,710 shares of the company’s stock worth $12,397,000 after buying an additional 841 shares in the last quarter. Burke & Herbert Bank & Trust Co. increased its holdings in shares of Johnson & Johnson by 2.6% during the first quarter. Burke & Herbert Bank & Trust Co. now owns 47,330 shares of the company’s stock worth $5,895,000 after buying an additional 1,218 shares in the last quarter. Oakbrook Investments LLC increased its holdings in shares of Johnson & Johnson by 7.4% during the second quarter. Oakbrook Investments LLC now owns 136,124 shares of the company’s stock worth $18,008,000 after buying an additional 9,375 shares in the last quarter. Finally, Paradigm Financial Advisors LLC increased its holdings in shares of Johnson & Johnson by 17.1% during the first quarter. Paradigm Financial Advisors LLC now owns 2,640 shares of the company’s stock worth $328,000 after buying an additional 386 shares in the last quarter. Institutional investors own 66.00% of the company’s stock.
Johnson & Johnson (JNJ) traded up 0.07% during mid-day trading on Friday, reaching $134.28. The company had a trading volume of 5,415,098 shares. The firm has a market capitalization of $360.41 billion, a price-to-earnings ratio of 22.72 and a beta of 0.79. The firm has a 50-day moving average price of $132.51 and a 200 day moving average price of $129.09. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.08.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.79 by $0.04. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The firm had revenue of $18.84 billion for the quarter, compared to analysts’ expectations of $18.94 billion. During the same quarter in the previous year, the company earned $1.74 earnings per share. The company’s revenue for the quarter was up 1.9% compared to the same quarter last year. Analysts expect that Johnson & Johnson will post $7.18 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th were given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.50%. The ex-dividend date of this dividend was Friday, August 25th. Johnson & Johnson’s payout ratio is 56.76%.
JNJ has been the subject of several research analyst reports. BidaskClub downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 1st. Cowen and Company reiterated a “buy” rating and set a $143.00 price target (up from $138.00) on shares of Johnson & Johnson in a report on Friday, May 19th. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $132.33 price target for the company in a report on Thursday, May 18th. BMO Capital Markets reiterated a “buy” rating and set a $132.00 price target on shares of Johnson & Johnson in a report on Friday, June 2nd. Finally, Royal Bank Of Canada reiterated a “buy” rating and set a $128.00 price target on shares of Johnson & Johnson in a report on Thursday, June 15th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $134.60.
In other Johnson & Johnson news, VP Dominic J. Caruso sold 82,591 shares of the business’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the transaction, the vice president now owns 226,693 shares in the company, valued at $30,993,466.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Paulus Stoffels sold 102,692 shares of the business’s stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the transaction, the vice president now owns 230,342 shares in the company, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.